Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma

被引:41
作者
Kudoh, K [1 ]
Kikuchi, Y [1 ]
Kita, T [1 ]
Tode, T [1 ]
Takano, M [1 ]
Hirata, J [1 ]
Mano, Y [1 ]
Yamamoto, K [1 ]
Nagata, I [1 ]
机构
[1] Natl Def Med Coll, Dept Obstet & Gynecol, Tokorozawa, Saitama 3598513, Japan
关键词
ovarian carcinoma; tumor marker; CA125; CA19-9; sialyl TN; tissue polypeptide antigen; carcinoembryonic antigen;
D O I
10.1159/000010062
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This study was designed to evaluate the clinical significance of the use of preoperative serum tumor markers in primary epithelial ovarian cancer. Subjects comprised 111 patients with primary epithelial ovarian cancer. Lactate dehydrogenase (LDH), alpha-hydroxybutyrate dehydrogenase (HBDH), carcinoembryonic antigen (CEA), CA19-9, tissue polypeptide antigen (TPA), CA125 and sialyl TN (STN) serum levels were measured within 7 days before surgery. The tumor marker values were compared with the histopathologic diagnosis. The overall agreement between the test results and the actual outcome was calculated using Student's t test and analysis of variance (AN OVA). Survival curves were constructed according to the Kaplan-Meier method, and differences in survival were assessed with the log-rank test. The prognostic significance of tumor markers for survival was assessed in a multivariate analysis with the Cox proportional hazards model. Of the tumor markers examined in this study, CA125 showed the highest positive rate (77.6%), followed by 63.2% for STN and 55.9% for CA19-9. When the positive rate was compared according to histologic types, serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid adenocarcinoma and clear cell carcinoma showed the highest positive rates for CA125 (94.1%), CA19-9 (76.9%), CA125 (91.7%) and STN (75.0%), respectively. Regarding the distribution of tumor marker levels according to the FIGO stage, LDH, HBDH, TPA and CA125 were correlated with the clinical stage while CEA, CA19-9 and STN did not show any correlation. From analyses of tumor marker levels according to histologic types, all patients with a ratio of CA125 to CEA of >1,000 had serous cystadenocarcinoma and a ratio of CA125 to CA19-9 of >50 showed serous cystadenocarcinoma or endometrioid adenocarcinoma. On the other hand, all patients with a ratio of LDH or HBDH to CA19-9 of <1.0 had mucinous cystadenocarcinoma or clear cell carcinoma. From univariate analysis, the survival time of patients with elevated CA125, TPA or STN was significantly shorter than that of patients with normal CA125, TPA or STN levels. When the Cox's proportional hazard model was used, we identified age, clinical stage, clear cell carcinoma and serum STN as independent prognostic factors. Serum CA125, TPA or STN may give significant prognostic information in epithelial ovarian carcinoma. It is noteworthy that STN has been identified as an independent prognostic factor and has a high rare of positivity in clear cell carcinoma.
引用
收藏
页码:52 / 57
页数:6
相关论文
共 15 条
[1]   MEDICAL PROGRESS - CANCER OF THE OVARY [J].
CANNISTRA, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (21) :1550-1559
[2]   Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease [J].
Goff, BA ;
delaCuesta, RS ;
Muntz, HG ;
Fleischhacker, D ;
Ek, M ;
Rice, LW ;
Nikrui, N ;
Tamimi, HK ;
Cain, JM ;
Greer, BE ;
Fuller, AF .
GYNECOLOGIC ONCOLOGY, 1996, 60 (03) :412-417
[3]  
Hiramatsu H, 1997, ONCOL REP, V4, P107
[4]  
KJELDSEN T, 1988, CANCER RES, V48, P2214
[5]   SIALYL TN AS A PROGNOSTIC MARKER IN EPITHELIAL OVARIAN-CANCER [J].
KOBAYASHI, H ;
TERAO, T ;
KAWASHIMA, Y .
BRITISH JOURNAL OF CANCER, 1992, 66 (05) :984-985
[6]  
MARSONI S, 1987, LANCET, V2, P353
[7]   AUTOMATED DETERMINATION OF NAD-COUPLED ENZYMES . DETERMINATION OF LACTIC DEHYDROGENASE [J].
MORGENSTERN, S ;
FLOR, R ;
KESSLER, G ;
KLEIN, B .
ANALYTICAL BIOCHEMISTRY, 1965, 13 (01) :149-+
[8]   Serum CA 125 levels and survival in advanced ovarian cancer [J].
Munstedt, K ;
Krisch, M ;
Sachsse, S ;
Vahrson, H .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1997, 259 (03) :117-123
[9]  
NISHIMURA H, 1997, J JPN SOC CANC THER, V32, P262
[10]  
OMURA G, 1986, CANCER, V57, P1725, DOI 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO